☰

Prashanth T. Bhaskar, Ph.D. - Publications

Affiliations: 
2008 University of Illinois at Chicago, Health Sciences Center, Chicago, IL 60612, United States 
Area:
Molecular Biology, Cell Biology
Tree Info Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Blaha CS, Ramakrishnan G, Jeon SM, Nogueira V, Rho H, Kang S, Bhaskar P, Terry AR, Aissa AF, Frolov MV, Patra KC, Brooks Robey R, Hay N. A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis. Nature Communications. 13: 899. PMID 35173161 DOI: 10.1038/s41467-022-28440-3  0.72
2015 Yu WN, Nogueira V, Sobhakumari A, Patra KC, Bhaskar PT, Hay N. Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration. Cell Reports. 12: 610-21. PMID 26190111 DOI: 10.1016/J.Celrep.2015.06.057  0.698
2013 Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey RB, Hay N. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 24: 213-28. PMID 23911236 DOI: 10.1016/J.Ccr.2013.06.014  0.591
2013 Patra K, Wang Q, Bhaskar P, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller W, Allen E, Jha A, Smolen G, Clasquin M, Robey R, Hay N. Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer Cancer Cell. 24: 399. DOI: 10.1016/J.Ccr.2013.08.029  0.552
2010 Chen CC, Jeon SM, Bhaskar PT, Nogueira V, Sundararajan D, Tonic I, Park Y, Hay N. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. Developmental Cell. 18: 592-604. PMID 20412774 DOI: 10.1016/J.Devcel.2010.03.008  0.748
2009 Bhaskar PT, Nogueira V, Patra KC, Jeon SM, Park Y, Robey RB, Hay N. mTORC1 hyperactivity inhibits serum deprivation-induced apoptosis via increased hexokinase II and GLUT1 expression, sustained Mcl-1 expression, and glycogen synthase kinase 3beta inhibition. Molecular and Cellular Biology. 29: 5136-47. PMID 19620286 DOI: 10.1128/Mcb.01946-08  0.748
2007 Bhaskar PT, Hay N. The two TORCs and Akt. Developmental Cell. 12: 487-502. PMID 17419990 DOI: 10.1016/J.Devcel.2007.03.020  0.602
2006 Skeen JE, Bhaskar PT, Chen CC, Chen WS, Peng XD, Nogueira V, Hahn-Windgassen A, Kiyokawa H, Hay N. Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. Cancer Cell. 10: 269-80. PMID 17045205 DOI: 10.1016/J.Ccr.2006.08.022  0.718
2004 Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Molecular Cell. 16: 819-30. PMID 15574336 DOI: 10.1016/J.Molcel.2004.11.014  0.559
Show low-probability matches.